Managing Severe MTHFR Deficiency Through Treatment
At a Glance
Severe MTHFR deficiency is treated with an individualized plan, usually centered on prescription betaine and regular blood tests. Active folate, B12, or methionine may be added to lower homocysteine, restore methionine, and reduce neurological risk.
Treating severe MTHFR deficiency is a highly specialized process that involves bypassing a “broken” genetic pathway to restore chemical balance in the body. Because this condition is so rare, there is no one-size-fits-all dosage [1]. Instead, your metabolic team will create an individualized treatment regimen—a combination of supplements and medications tailored specifically to your blood levels of homocysteine and methionine [2][3].
The goal of treatment is twofold: to lower toxic homocysteine levels and to raise methionine levels as close to the normal range as possible to protect the brain and nervous system [1][3].
Betaine Anhydrous: The Core Treatment
Betaine anhydrous (often prescribed as the brand Cystadane) is the most critical part of treatment for severe MTHFR deficiency [1][3]. In your body, the MTHFR enzyme is supposed to help recycle homocysteine into methionine. When it doesn’t work, betaine acts as a “backup worker” [4].
It uses an alternative route (the BHMT pathway) in the liver to perform this recycling. By giving the body extra betaine, you provide the tools needed to clear homocysteine and produce more methionine [4].
- Dosing: Betaine is usually given in multiple doses throughout the day. While registry data has observed some older patients taking around 9 grams per day, this is a clinical observation, not a target dose. Your doctor will start with a dose based on weight and increase it gradually based on your blood tests [5][6]. You must never change the dose independently, and you must distinguish prescription betaine anhydrous from over-the-counter betaine or TMG.
- Safety Warning: Betaine is highly effective, but excessive amounts can drive methionine dangerously high. Cerebral edema (brain swelling) has been reported in patients with remethylation disorders receiving betaine. Strict plasma-methionine monitoring is mandatory. Seek urgent medical advice for severe headache, vomiting, confusion, or reduced consciousness.
- Tolerability: Betaine is generally well-tolerated. Some people notice a slight “fishy” body odor, which is caused by how the body breaks down the medication, but serious side effects are very rare [5]. Discuss practical medication advice with your team, such as mixing, storage, and handling missed doses.
The Role of Folate (5-MTHF)
While many people take standard folic acid, it may not be the best choice for someone with a severe MTHFR deficiency. The MTHFR enzyme’s job is to convert folate into its active form, called 5-methyltetrahydrofolate (5-MTHF) [7].
Because people with this condition cannot make that conversion effectively, some specialists may prescribe the active form directly (sometimes called calcium mefolinate) [4].
- Brain Protection: Some research and case reports suggest that in severe cases, active 5-MTHF may cross the blood-brain barrier and reach the central nervous system more effectively than standard folic acid or folinic acid [4][8]. However, the choice of folate formulation is specialist-dependent. Do not change your prescribed folate product without your metabolic team’s orders.
Vitamin B12 (Hydroxocobalamin)
When a doctor first suspects a “remethylation disorder” (the category that MTHFR deficiency falls into), they will often start immediate injections of hydroxocobalamin (a form of Vitamin B12) [3]. This is a “safety first” approach.
Some other rare disorders that look like MTHFR deficiency are caused by B12 processing problems and require these injections to prevent permanent damage [1][3]. Once genetic testing confirms that the problem is specifically the MTHFR gene, your doctor will decide if B12 injections should continue. Do not stop B12 without your metabolic team, as it is needed for downstream reactions [1].
Methionine Supplementation
Because the recycling process is broken, many patients have chronically low levels of methionine. Methionine is an essential amino acid and a vital precursor for methylation reactions [4].
If betaine and folate are not enough to bring methionine levels into the normal range, your doctor may add oral methionine supplements to the daily regimen [2][9]. This is carefully monitored with frequent blood tests to ensure levels don’t become too high.
Individualized Titration and Monitoring
Treatment for MTHFR deficiency is not “set it and forget it.” It requires lifelong monitoring by a metabolic specialist.
- Frequent Blood Tests: Especially in the beginning or during growth spurts, you will need frequent blood draws to check total homocysteine and plasma amino acids (to check methionine) [1][10].
- Targeting the “Sweet Spot”: Your doctor is looking for the minimum dose of medications that keeps homocysteine low and methionine healthy.
- Growth and Change: As a child grows or an adult’s health status changes, doses must be adjusted. Pregnancy, illness, or surgery are all times when the treatment regimen may need temporary adjustment [1][11].
Early and consistent treatment is the best way to prevent the neurological and vascular complications associated with this condition [3]. By strictly following the prescribed supplement schedule, many patients can achieve significant improvements in their health and quality of life [2].
Common questions in this guide
What does treatment for severe MTHFR deficiency involve?
Why is betaine used for MTHFR deficiency?
Can too much betaine cause a serious problem?
Is 5-MTHF better than folic acid for MTHFR deficiency?
Are B12 injections needed after MTHFR deficiency is confirmed?
When are methionine supplements added?
Get notified when new evidence is published on Homocystinuria due to methylene tetrahydrofolate reductase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.
Olivieri G, Bordugo A, Burnyte B, et al.
Journal of inherited metabolic disease 2026; (49(4)):e70177 doi:10.1002/jimd.70177.
PMID: 42231716 - 2
Clinical pattern, mutations and in vitro residual activity in 33 patients with severe 5, 10 methylenetetrahydrofolate reductase (MTHFR) deficiency.
Huemer M, Mulder-Bleile R, Burda P, et al.
Journal of inherited metabolic disease 2016; (39(1)):115-24 doi:10.1007/s10545-015-9860-6.
PMID: 26025547 - 3
Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency.
Huemer M, Diodato D, Schwahn B, et al.
Journal of inherited metabolic disease 2017; (40(1)):21-48 doi:10.1007/s10545-016-9991-4.
PMID: 27905001 - 4
Treatment with Mefolinate (5-Methyltetrahydrofolate), but Not Folic Acid or Folinic Acid, Leads to Measurable 5-Methyltetrahydrofolate in Cerebrospinal Fluid in Methylenetetrahydrofolate Reductase Deficiency.
Knowles L, Morris AA, Walter JH
JIMD reports 2016; (29()):103-107 doi:10.1007/8904_2016_529.
PMID: 26898294 - 5
Betaine anhydrous in homocystinuria: results from the RoCH registry.
Valayannopoulos V, Schiff M, Guffon N, et al.
Orphanet journal of rare diseases 2019; (14(1)):66 doi:10.1186/s13023-019-1036-2.
PMID: 30871635 - 6
Postauthorization safety study of betaine anhydrous.
Mütze U, Gleich F, Garbade SF, et al.
Journal of inherited metabolic disease 2022; (45(4)):719-733 doi:10.1002/jimd.12499.
PMID: 35358327 - 7
Functional characterization of missense mutations in severe methylenetetrahydrofolate reductase deficiency using a human expression system.
Burda P, Suormala T, Heuberger D, et al.
Journal of inherited metabolic disease 2017; (40(2)):297-306 doi:10.1007/s10545-016-9987-0.
PMID: 27743313 - 8
Determination of CSF 5-methyltetrahydrofolate in children and its application for defects of folate transport and metabolism.
Akiyama M, Akiyama T, Kanamaru K, et al.
Clinica chimica acta; international journal of clinical chemistry 2016; (460()):120-5.
PMID: 27363740 - 9
Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency.
Rommer PS, Zschocke J, Fowler B, et al.
Journal of the neurological sciences 2017; (383()):123-127 doi:10.1016/j.jns.2017.10.035.
PMID: 29246599 - 10
Influence of early identification and therapy on long-term outcomes in early-onset MTHFR deficiency.
Yverneau M, Leroux S, Imbard A, et al.
Journal of inherited metabolic disease 2022; (45(4)):848-861 doi:10.1002/jimd.12504.
PMID: 35460084 - 11
A Pediatric Case of Homocystinuria Due to MTHFR Deficiency with Early Clinical Features Resembling Leigh Encephalopathy.
Itabashi T, Abe J, Nakajima M, et al.
Children (Basel, Switzerland) 2026; (13(10)) doi:10.3390/children13101332.
PMID: 42940651
This page explains treatment options and monitoring for severe MTHFR deficiency for informational purposes only. Do not change betaine, folate, B12, or methionine treatment without guidance from your metabolic team.